Arbutus to participate in h.c wainwright @ home virtual fireside chat

Warminster, pa., nov. 26, 2024 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), (“arbutus” or the “company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis b virus (chbv) infection, today announced that the company will participate in the virtual h.c wainwright @ home fireside chat series taking place on tuesday, december 3, 2024 at 11:00 am et.
ABUS Ratings Summary
ABUS Quant Ranking